Zhao Xinyi, Javed Bilal, Tian Furong, Liu Kangze
School of Food Science and Environmental Health, Technological University Dublin, D07 EWV4 Dublin, Ireland.
School of Chemistry, Chemical Engineering, and Biotechnology, Nanyang Technological University, Singapore 639798, Singapore.
Gels. 2022 Oct 17;8(10):664. doi: 10.3390/gels8100664.
Glioma is considered the primary brain tumor to cause brain illnesses, and it is difficult to treat and shows resistance to various routine therapeutics. The most common treatments to cure glioma are the surgical removal of tumors followed by adjuvant chemotherapy and radiation therapy. The latest biocompatible interfaces have been incorporated into therapeutic modalities such as the targeted delivery of drugs using hydrogels to treat and manage brain glioma. This review illustrates the applications of the multimodal hydrogel as the carrier of therapeutics, gene therapy, therapeutic tactics, and glioma devices. The scientific articles were retrieved from 2019 to 2022 on Google Scholar and the Scopus database and screened to determine whether they were suitable for review. The 20 articles that fit the study are summarized in this review. These studies indicated that the sizes of the hydrogel range from 28 nm to 500 nm. There are 16 out of 20 articles that also explain the post-surgical application of hydrogels, and 13 out of 20 articles are employed in 3D culture and other structural manifestations of hydrogels. The pros of the hydrogel include the quick formulation for a sufficient filling of irregular damage sites, solubilizing hydrophobic drugs, continuously slowing drug release, provision of a 3D cell growth environment, improving efficacy, targetability of soluble biomolecules, increasing patient compliance, and decreased side effects. The cons of the hydrogel include difficult real-time monitoring, genetic manipulations, the cumbersome synchronized release of components, and lack of safety data. The prospects of the hydrogel may include the development of electronic hydrogel sensors that can be used to enhance guidance for the precise targeting patterns using patient-specific pathological idiosyncrasies. This technology has the potential to revolutionize the precision medicine approaches that would aid in the early detection and management of solid brain tumors.
神经胶质瘤被认为是导致脑部疾病的原发性脑肿瘤,它难以治疗且对各种常规疗法均表现出耐药性。治疗神经胶质瘤最常见的方法是手术切除肿瘤,随后进行辅助化疗和放射治疗。最新的生物相容性界面已被纳入治疗模式,例如使用水凝胶进行药物靶向递送以治疗和管理脑胶质瘤。这篇综述阐述了多模态水凝胶作为治疗剂载体、基因治疗、治疗策略和神经胶质瘤装置的应用。从2019年到2022年在谷歌学术搜索和Scopus数据库中检索科学文章,并进行筛选以确定它们是否适合综述。本综述总结了符合该研究的20篇文章。这些研究表明,水凝胶的尺寸范围为28纳米至500纳米。20篇文章中有16篇还解释了水凝胶的术后应用,20篇文章中有13篇用于水凝胶的三维培养和其他结构表现。水凝胶的优点包括快速配制以充分填充不规则损伤部位、溶解疏水性药物、持续减缓药物释放、提供三维细胞生长环境、提高疗效、可溶性生物分子的靶向性、提高患者依从性以及减少副作用。水凝胶的缺点包括难以进行实时监测、基因操作、成分同步释放繁琐以及缺乏安全数据。水凝胶的前景可能包括开发电子水凝胶传感器,可用于利用患者特定的病理特质增强对精确靶向模式的指导。这项技术有可能彻底改变精准医学方法,有助于早期检测和管理实体脑肿瘤。